Calliditas Interim Report January to June 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2024
0mins
Source: PRnewswire
Financial Performance: Calliditas Therapeutics reported significant growth in net sales for Q2 2024, reaching SEK 559.8 million compared to SEK 269.4 million in Q2 2023, with TARPEYO® contributing SEK 493.4 million. The operating loss decreased from SEK 75.2 million in 2023 to SEK 31.5 million in 2024, and adjusted operating profit stood at SEK 70.2 million after accounting for specific expenses.
Key Developments: In Q2 2024, Calliditas achieved positive trial results for Nefecon and setanaxib, launched Nefecon in China through a partner, and received a favorable opinion for Kinpeygo® in the EU. Additionally, Asahi Kasei Corporation made a public cash offer to acquire Calliditas, which is currently under consideration until August 30, 2024.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
